{"id":"met-vildagliptin-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL142703","moleculeType":"Small molecule","molecularWeight":"303.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"This combination uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:28.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01867502","phase":"PHASE4","title":"Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring","enrollment":20},{"nctId":"NCT00975065","phase":"PHASE4","title":"Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Galvus®","Glyburide","Glucophage"],"phase":"marketed","status":"active","brandName":"MET + Vildagliptin Group","genericName":"MET + Vildagliptin Group","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}